Skip to main content
Premium Trial:

Request an Annual Quote

DNAPrint Acquires Ellipsis Biotherapeutics in All-Stock Deal

NEW YORK, Nov. 15 (GenomeWeb News) - DNAPrint Genomics said today that it will acquire the core clinical genomics and genotyping assets of Ellipsis Biotherapeutics in an all-stock transaction.

 

Under the terms of the agreement, Ellipsis will sell its core assets in exchange for 6,500,000 shares of DNAPrint Genomics' common stock. Based on DNAPrint's share price today, the deal would be worth approximately $112,000. The transaction is expected to be completed by Nov. 30.

 

DNAPrint said it will retain Ellipsis' employees and business operations, and will retain the Ellipsis Biotherapeutics name as a subsidiary.

 

This is the fourth major acquisition that DNAPrint has made in the past six months. In June, the company acquired Trace Genetics in an all-stock deal; in July, the firm bought 18 percent of BioFrontera for approximately $1.8 million; and earlier this month DNAPrint purchased Kenna Technologies in another all-stock deal.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.